即时询价 ×
* 必填项
请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
CAS号 | 1388803-90-4 | 货号 | BCP43522 |
中文名 | Vodobatinib | ||
英文名 | Vodobatinib | ||
中文别名 | |||
英文别名 | K-0706; K0706; K0706; | ||
SMILES | CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3 | ||
化学名称 | |||
分子式 | C27H20ClN3O2 | 分子量 | 453.92 |
纯度 | 98% | 配送 | 惯例下常温包邮 |
产品描述 | Vodobatinib is an orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis. |
Tags:Vodobatinib 供应商,Vodobatinib 购买,Vodobatinib 生产,Vodobatinib 批量,Vodobatinib 供应,Vodobatinib 订购,Vodobatinib 采购